Paroxysmal Nocturnal Hemoglobinuria Drug Market, By Treatment, By Drugs, By Route of Administration, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030

List of Tables

REPORT HIGHLIGHT

Paroxysmal Nocturnal Hemoglobinuria Drug Market size was valued at USD 3,470.2 Million in 2022, expanding at a CAGR of 13.8% from 2023 to 2030.

Red blood cells are destroyed (hemolyzed) and aberrant red blood cells are present in the circulation in paroxysmal nocturnal hemoglobinuria (PNH), an uncommon and possibly fatal blood condition. It results from excessive activation of the complement system, a component of the immune system in charge of removing foreign substances in the body, which is brought on by a genetic mutation that affects the proteins on the surface of red blood cells.

Paroxysmal Nocturnal Hemoglobinuria Drug Market - Market Dynamics:

Growing regulatory approvals and R&D drives market growth

The developments of the worldwide paroxysmal nocturnal hemoglobinuria medicine market heavily depend on regulatory approvals from organizations like the European Medicines Agency (EMA), the U.S. Food and medicine Administration (FDA), and other international regulatory agencies. Eculizumab and ravulizumab's market presence and patient accessibility have benefited from their approval, which has laid a solid basis. Additionally, attempts to discover novel therapy alternatives and enhance existing therapies are the main goals of continuing research and development in the field of PNH. This includes investigating combination medicines, developing innovative targeted therapeutics, and alternate administration techniques. These developments and breakthroughs help the PNH drugs industry expand and develop.

Paroxysmal Nocturnal Hemoglobinuria Drug Market - Key Insights:

As per the analysis shared by our research analyst, the global Paroxysmal Nocturnal Hemoglobinuria Drug market is estimated to grow annually at a CAGR of around 13.8% over the forecast period (2023-2030)

The Paroxysmal Nocturnal Hemoglobinuria Drug industry is projected to grow at a significant rate owing to the growing regulatory approvals

Based on treatment, the blood transfusion segment is expected to dominate the market over the forecast period

Based on region, North America is expected to dominate the market over the forecast period

Paroxysmal Nocturnal Hemoglobinuria Drug Market- Segmentation Analysis:

The Global Paroxysmal Nocturnal Hemoglobinuria Drug Market is segmented based on treatment, drugs, route of administration, end user, and Region.

Based on treatment, the market is bifurcated into medication, supplements, blood transfusion, and bone marrow transplants. The blood transfusion segment is expected to dominate the market over the forecast period. Blood transfusion is one of the therapies that might help to lessen the symptoms of anemia. PNH causes major adverse effects including thrombosis and can be deadly if left untreated. PNH patients frequently require blood transfusions to treat their anemic symptoms because, during a transfusion, the patients receive blood or blood products from a donor. Thus, driving the market growth.

Paroxysmal Nocturnal Hemoglobinuria Drug Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market over the forecast period. Major pharmaceutical firms that create and promote targeted therapy for PNH dominate the region's PNH medication market. Companies like Alexion Pharmaceuticals, which is now a division of AstraZeneca, and the medicine eculizumab (marketed under the name Soliris), have had a substantial impact on the market environment. Additionally, the approval and availability of PNH medications are greatly influenced by the regulatory climate in North America, notably the United States. Targeted treatments for the treatment of PNH, such as eculizumab and ravulizumab (marketed under the brand Ultomiris), have been approved by the U.S. Food and Drug Administration (FDA), which has contributed to their extensive usage in the area.

Paroxysmal Nocturnal Hemoglobinuria Drug Market- Competitive Landscape:

Leading companies in the worldwide Deepwater Hydrocarbon Exploration market are stepping up their R&D efforts to diversify their product offerings. Additionally, these market participants use strategic alliances and partnerships that promote growth. The key players operating in the market include Ra Pharmaceuticals Inc, CinnaGen Co, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc, Apellis Pharmaceuticals, Abbott, NorthStar Rx LLC, Alnylam Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Regeneron Pharmaceuticals Inc, BIOCAD, Samsung Bioepis, Amyndas Pharmaceuticals, Teva Pharmaceutical Industries Ltd., LGM Pharma., Lannett, Achillion Pharmaceuticals Inc and Amgen Inc.

Recent Developments:

In September 2023, the US Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for crovalimab, an experimental, brand-new anti-C5 recycling monoclonal antibody, to treat paroxysmal nocturnal hemoglobinuria (PNH), according to Chugai Pharmaceutical Co., Ltd. The acceptance was based on the key phase III COMMODORE 2 study's findings, which showed that crovalimab effectively controlled illness and was well tolerated in PNH patients.1 Crovalimab's constant benefit-risk profile as seen in the phase III COMMODORE 1 study's findings provided additional evidence for the application.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET KEY PLAYERS

Ra Pharmaceuticals Inc
CinnaGen Co
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Apellis Pharmaceuticals
Abbott
NorthStar Rx LLC
Alnylam Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Novartis AG
Regeneron Pharmaceuticals Inc
BIOCAD
Samsung Bioepis
Amyndas Pharmaceuticals
Teva Pharmaceutical Industries Ltd.
LGM Pharma.
Lannett
Achillion Pharmaceuticals Inc
Amgen Inc

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY TREATMENT

Medication
Supplements
Blood Transfusion
Bone Marrow Transplant

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY DRUGS

Eculizumab
Ravulizumab
Others

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY ROUTE OF ADMINISTRATION

Oral
Parenteral

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY END USER

Hospitals
Homecare
Specialty Clinics
Others

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY REGION

North America

The U.S.
Canada

Europe

Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe

Asia Pacific

India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC

Latin America

Brazil
Mexico
Argentina
Colombia
Rest of LATAM

The Middle East and Africa

Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV1670

1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Treatment
- 2.1.2. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Drugs
- 2.1.3. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Route of Administration
- 2.1.4. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by End User
- 2.1.5. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Country
- 2.1.6. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Region
2.2. Competitive Insights

3. Paroxysmal Nocturnal Hemoglobinuria Drug Key Market Trends

3.1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Paroxysmal Nocturnal Hemoglobinuria Drug Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Paroxysmal Nocturnal Hemoglobinuria Drug Market Opportunities
3.4. Paroxysmal Nocturnal Hemoglobinuria Drug Market Future Trends

4. Paroxysmal Nocturnal Hemoglobinuria Drug Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Paroxysmal Nocturnal Hemoglobinuria Drug Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Paroxysmal Nocturnal Hemoglobinuria Drug Market Landscape

6.1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Share Analysis, 2022
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By Treatment

7.1. Overview
- 7.1.1. Segment Share Analysis, By Treatment, 2022 & 2030 (%)
- 7.1.2. Medication
- 7.1.3. Supplements
- 7.1.4. Blood Transfusion
- 7.1.5. Bone Marrow Transplant

8. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By Drugs

8.1. Overview
- 8.1.1. Segment Share Analysis, By Drugs, 2022 & 2030 (%)
- 8.1.2. Eculizumab
- 8.1.3. Ravulizumab
- 8.1.4. Others

9. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By Route of Administration

9.1. Overview
- 9.1.1. Segment Share Analysis, By Route of Administration, 2022 & 2030 (%)
- 9.1.2. Oral
- 9.1.3. Parenteral

10. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By End User

10.1. Overview
- 10.1.1. Segment Share Analysis, By End User, 2022 & 2030 (%)
- 10.1.2. Hospitals
- 10.1.3. Homecare
- 10.1.4. Specialty Clinics
- 10.1.5. Others

11. Paroxysmal Nocturnal Hemoglobinuria Drug Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.3.9. Italy
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.3.9.3. Italy Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.3.9.4. Italy Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.3.9.6. Italy Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.3.10. United Kingdom
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.3.10.3. United Kingdom Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.3.10.4. United Kingdom Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.3.10.6. United Kingdom Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.3.11. France
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.3.11.3. France Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.3.11.4. France Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.3.11.6. France Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.3.12. Russia
  - 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.3.12.2. Russia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.3.12.3. Russia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.3.12.5. Russia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.3.13. Netherlands
  - 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.3.13.2. Netherlands Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.3.13.3. Netherlands Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.3.13.5. Netherlands Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.3.14.2. Sweden Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.3.15. Poland
  - 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.3.15.2. Poland Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.3.15.3. Poland Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.3.15.5. Poland Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.3.16. Rest of Europe
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.3.16.3. Rest of the Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.3.16.6. Rest of the Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Asia Pacific
- 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 11.4.4. Asia Pacific Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
- 11.4.5. Asia Pacific Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
- 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
- 11.4.7. Asia Pacific Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.4.8. India
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.4.8.3. India Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.4.8.4. India Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.4.8.6. India Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.4.9. China
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.4.9.3. China Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.4.9.4. China Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.4.9.6. China Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.4.13. Thailand
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.4.13.3. Thailand Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.4.13.4. Thailand Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.4.13.6. Thailand Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.4.14. Indonesia
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.4.14.3. Indonesia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.4.14.4. Indonesia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.4.14.6. Indonesia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.5. Latin America
- 11.5.1. Overview
- 11.5.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Latin America
- 11.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 11.5.4. Latin America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
- 11.5.5. Latin America Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
- 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
- 11.5.7. Latin America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.6. Middle East and Africa
- 11.6.1. Overview
- 11.6.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Middle East and Africa
- 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 11.6.4. Middle East and Africa Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
- 11.6.5. Middle East and Africa Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
- 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
- 11.6.7. Middle East and Africa Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)

12. Key Vendor Analysis- Paroxysmal Nocturnal Hemoglobinuria Drug Industry

12.1. Competitive Dashboard
12.2. Company Profiles
- 12.2.1. Ra Pharmaceuticals Inc
- 12.2.2. CinnaGen Co
- 12.2.3. Akari Therapeutics Plc
- 12.2.4. Alexion Pharmaceuticals Inc
- 12.2.5. Apellis Pharmaceuticals
- 12.2.6. Abbott
- 12.2.7. NorthStar Rx LLC
- 12.2.8. Alnylam Pharmaceuticals Inc
- 12.2.9. F. Hoffmann-La Roche Ltd
- 12.2.10. Novartis AG
- 12.2.11. Regeneron Pharmaceuticals Inc
- 12.2.12. BIOCAD
- 12.2.13. Samsung Bioepis
- 12.2.14. Amyndas Pharmaceuticals
- 12.2.15. Teva Pharmaceutical Industries Ltd.
- 12.2.16. LGM Pharma.
- 12.2.17. Lannett
- 12.2.18. Achillion Pharmaceuticals Inc
- 12.2.19. Amgen Inc

13. 360 Degree Analyst View

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us

Product Code: ANV1670

List of Tables

TABLE List of data sources
TABLE Market drivers; Impact Analysis
TABLE Market restraints; Impact Analysis
TABLE Paroxysmal Nocturnal Hemoglobinuria Drug Market: Treatment Snapshot (2022)
TABLE Segment Dashboard; Definition and Scope, by Treatment
TABLE Global Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment 2018-2030 (USD Million)
TABLE Paroxysmal Nocturnal Hemoglobinuria Drug Market: Drugs Snapshot (2022)
TABLE Segment Dashboard; Definition and Scope, by Drugs
TABLE Global Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs 2018-2030 (USD Million)
TABLE Paroxysmal Nocturnal Hemoglobinuria Drug Market: Route of Administration Snapshot (2022)
TABLE Segment Dashboard; Definition and Scope, by Route of Administration
TABLE Global Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration 2018-2030 (USD Million)
TABLE Paroxysmal Nocturnal Hemoglobinuria Drug Market: End User Snapshot (2022)
TABLE Segment Dashboard; Definition and Scope, by End User
TABLE Global Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User 2018-2030 (USD Million)
TABLE Paroxysmal Nocturnal Hemoglobinuria Drug Market: Regional snapshot (2022)
TABLE Segment Dashboard; Definition and Scope, by Region
TABLE Global Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Region 2018-2030 (USD Million)
TABLE North America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Country, 2018-2030 (USD Million)
TABLE North America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment, 2018-2030 (USD Million)
TABLE North America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs, 2018-2030 (USD Million)
TABLE North America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration, 2018-2030 (USD Million)
TABLE North America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User, 2018-2030 (USD Million)
TABLE Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Country, 2018-2030 (USD Million)
TABLE Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment, 2018-2030 (USD Million)
TABLE Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs, 2018-2030 (USD Million)
TABLE Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration, 2018-2030 (USD Million)
TABLE Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User, 2018-2030 (USD Million)
TABLE Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Country, 2018-2030 (USD Million)
TABLE Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment, 2018-2030 (USD Million)
TABLE Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs, 2018-2030 (USD Million)
TABLE Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration, 2018-2030 (USD Million)
TABLE Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User, 2018-2030 (USD Million)
TABLE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Country, 2018-2030 (USD Million)
TABLE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment, 2018-2030 (USD Million)
TABLE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs, 2018-2030 (USD Million)
TABLE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration, 2018-2030 (USD Million)
TABLE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User, 2018-2030 (USD Million)
TABLE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Country, 2018-2030 (USD Million)
TABLE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment, 2018-2030 (USD Million)
TABLE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs, 2018-2030 (USD Million)
TABLE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration, 2018-2030 (USD Million)
TABLE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User, 2018-2030 (USD Million)

Paroxysmal Nocturnal Hemoglobinuria Drug Market, By Treatment, By Drugs, By Route of Administration, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030

Description

Table of Contents

List of Tables

REPORT HIGHLIGHT

Paroxysmal Nocturnal Hemoglobinuria Drug Market - Market Dynamics:

Paroxysmal Nocturnal Hemoglobinuria Drug Market - Key Insights:

Paroxysmal Nocturnal Hemoglobinuria Drug Market- Segmentation Analysis:

Paroxysmal Nocturnal Hemoglobinuria Drug Market- Geographical Insights

Paroxysmal Nocturnal Hemoglobinuria Drug Market- Competitive Landscape:

Recent Developments:

SCOPE OF THE REPORT

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET KEY PLAYERS

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY TREATMENT

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY DRUGS

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY ROUTE OF ADMINISTRATION

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY END USER

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY REGION

Table of Contents

1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Overview

2. Executive Summary

3. Paroxysmal Nocturnal Hemoglobinuria Drug Key Market Trends

4. Paroxysmal Nocturnal Hemoglobinuria Drug Industry Study

5. Paroxysmal Nocturnal Hemoglobinuria Drug Market: COVID-19 Impact Analysis

6. Paroxysmal Nocturnal Hemoglobinuria Drug Market Landscape

7. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By Treatment

8. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By Drugs

9. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By Route of Administration

10. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By End User

11. Paroxysmal Nocturnal Hemoglobinuria Drug Market- By Geography

12. Key Vendor Analysis- Paroxysmal Nocturnal Hemoglobinuria Drug Industry

13. 360 Degree Analyst View

14. Appendix

List of Tables